Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**AUROBINDO PHARMA LIMITED – FINANCIAL RISK SUMMARY** Aurobindo Pharma faces critical compliance exposure under SEBI BRSR Core Expansion requirements, with a maximum estimated remediation cost of ₹190 crore and potential delisting risk if environmental and social disclosures remain non-compliant across Principle 6 standards. The company's 10.0/10 compliance risk score is the dominant financial threat, compounded by unclear Extended Producer Responsibility (EPR) applicability—failure to determine and execute EPR obligations could trigger unquantified regulatory penalties and operational disruptions in pharmaceutical packaging. While GHG and water intensity risks are moderate (5.0/10 each), the absence of reported Scope 1 and 2 emissions data suggests measurement gaps rather than zero impact, leaving the company exposed to retroactive carbon pricing liabilities under India's Carbon Credit Trading Scheme (₹600–900/tonne) once emissions are properly quantified. Immediate priority actions include formal BRSR compliance audit, EPR classification confirmation, and establishment of robust GHG accounting to mitigate enforcement action risk.
Source: AUROBINDO PHARMA LIMITED BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.